Posts tagged Antiretroviral drugs
HIV Treatment Funding Is Out of Reach for Countries in Need
The battle against HIV has come a long way. Those living with the infection benefit from therapies now available. One of these benefits is a longer life expectancy. Worldwide, these implemented treatments not only improve quality and quantity of life, but it also limits the spread of the disease. Unfortunately, longer life equals more expense in lifetime treatment costs, which underdeveloped nations cannot support.
In spite of the good things being accomplished, the cost of maintaining what had been put into effect is already high and is increasing. Some of the countries hardest hit by HIV will experience the biggest cuts in funding. For these areas, future long-term care could be compromised. In Sub-Saharan Africa, home to some of the countries with the highest cases of HIV infections, studies were done to determine the cost of long-term therapy. The numbers are staggering. In order to maintain current treatment, account for new cases, and continue with prevention plans through the year 2050, it is estimated to cost over $260 billion. It’s a figure African countries simply can’t sustain.
Some Countries with the Greatest Need Have the Least Resources
The areas that were investigated are the ones that account for well over two-thirds of HIV infections in all of Africa. These nations do not have the resources to continue to provide necessary and ongoing care for HIV patients. Experts feel it’s vital to collect the needed funding now to ensure it is there for the future. Otherwise, lack of funds for treatment could lead to an increased prevalence of AIDS, as well as an increase in the spread of HIV.
As previously mentioned, long-term care is important for each individual who is HIV-positive. Part of the treatments include inhibiting the transfer of the virus. Stopping the spread of the disease is vital. Researchers emphasized the need for continued support in the fight against HIV, not only for the financial reasons but the moral ones as well. With so many people able to have a relatively healthy and normal life because of current plans in place, their lives are dependent on continued care and the funding that backs it.
HIV Therapies According to Gender
8 years ago
by ADMIN
in HIV Therapy
The approach to treating HIV is similar for all—male and female, young and old. Adjustments can be made according to certain factors. A particular dosage may work for one, but may not be optimal for another. One recently published study shows why this can happen, and how medical professionals can increase the effectiveness of HIV therapies for their patients.
HIV Therapies and Gender
Preventing infection is an important part of curbing the spread of HIV. The drug used to prevent viral transfer is called Truvada. Until recently, it had been noted that the drug was most effective in men. Researchers found that it seemed less effective in women. Further investigation revealed that differences in tissues contributed to how well Truvada worked at preventing infection.
HIV needs access to genetic material in order to infect its host. The more DNA that is present, the stronger the viral hold. For women, vaginal and cervical tissues have more DNA present than in other types of tissue. Rectal tissue is also in this category. This requires considerable more medication to curtail HIV activity.
Armed with this knowledge, scientists mathematically calculated specific drugs-to-DNA ratios. Using this formula, and testing the outcomes, has proven successful. When increased doses were given to women, the rate of HIV infections decreased and more closely matched the male outcomes based on doses previously tried.
What does this mean for HIV therapies now? In short, women do best when taking Truvada every day. This contrasts considerably to the couple times a week generally prescribed. For the male population, the current dosage works well. Due to the anatomical differences, women require more of the medication. When taken daily, the rate of infection effectively decreases for this group. Of course, no one should change his or her therapy before consulting a healthcare provider.
So far, Truvada is the only FDA-approved pharmaceutical used to prevent the spread of HIV infections. Now with more information on how best to harness its potential, the medical world is in a good position to help keep others from contracting and spreading the virus.
Potential Key to a Cure for HIV
Antiretroviral therapies are efficient at lowering HIV levels in the blood. They suppress these levels enough that the virus can become virtually undetectable, making it hard to cure. While this provides the patient with a measure of health, and also slows disease progression, it is not enough to completely eradicate the virus from the body. Why is this the case? What is the key to eliminating the tenacious invader completely so as to have a cure?
Progress Towards a Cure
Study after study continues to show that antiretroviral therapy alone cannot completely rid the body of HIV. It is true that low viral levels within the blood can prove lifesaving, but HIV finds a way to hide, replicate, and even thrive. Attempting to kill off the virus in these areas is the key to completely wiping it out. Blood levels can be kept low because the drugs can effectively work within the vascular network. Researchers are finding that stores of HIV are located within the lymphatic system, specifically in lymph nodes and like tissues.
This presents challenges for healthcare. One, it is difficult for pharmaceuticals to reach the specific tissues where the virus replicates. It is rare for medications to filter into these lymph nodes. Also, there is the matter of viral mutation. As HIV patients increase in numbers, changes in the disease’s resistance to drugs begins to appear.
The good news is that usually it is the non-resistant form of the virus that hides and replicates. Once it releases into the blood, the drug therapies are still effective. Also, when researchers exposed the infected tissues to the drugs, the infection could be cleared. However, depending on the type and concentration of the drug therapy, the amount of drug-resistant HIV can fluctuate, making things complicated.
Further investigation is underway about how to infiltrate lymphatic tissue in order to remove stores of HIV. Researchers are convinced that once they gain a better understanding of how to reach these areas—combined with antiretroviral therapies—a cure for HIV will be at hand. Until then, daily treatment is the only way to keep the disease from progressing.
HIV and Stroke Are Linked – Long-Term Treatment Reduces Risk
8 years ago
HIV has long been connected with certain secondary conditions and complications. With treatment, some can be managed, and risks can be reduced. One surprising study has revealed a strong link between HIV and stroke. It had been noticed that the number of young individuals presenting with a stroke were HIV-positive. New studies have found definite ties between the two conditions.
The trend has been noted especially across much of the southern portion of Africa.
- Young adults reporting stroke had no history to suggest risk.
- For example, few had a history of high blood pressure, were obese, smoked, or had diabetes.
- Researchers found that in one study, almost half of the participants who had strokes were HIV positive.
- These individuals were all under 45 years old.
- Consistent with what was being seen, these patients also had no previous history that would suggest a high risk of stroke.
Another interesting piece of information that had been uncovered during the ongoing study was that those who had just started therapy for HIV had the highest risk of stroke. The risk declined after six months of treatment. Those who had been on the antiretroviral therapies for a while had a much lower risk of stroke. Medical personnel are eager to learn what the specific link is between the virus and stroke. Particularly alarming is the high risk during the first stages of the therapy.
What Does the HIV and Stroke Link Mean Globally?
While these findings were uncovered on the African continent, the link between HIV and stroke is definite. The findings here will have tremendous effects globally when it comes to HIV and its treatment.
There is clear evidence that continued treatment not only maintains health and controls the HIV infection, but also greatly reduces stroke risk. Bridging the gap between the starting point and less risk is now the main focus. Continued investigation is necessary at this juncture to find answers, and then come up with ways to protect patients until they are out of the high-risk category.
Low Risk of Birth Defects
9 years ago
by ADMIN
in HIV and Pregnancy
Low Risk of Birth Defects: HIV and Antiretroviral Medication
With new compounds and therapies expanding what can be done for individuals living with HIV, more and more infected women are looking towards pregnancy and childbirth. The combination of pregnancy and the latest antiviral medications is always a cause of concern, as we often don’t have enough data to make a definitive decision on whether a certain medicine should be given to an individual while pregnant. We also need to know when it is most likely for a mother to infect her infant, and which medicines are best at keeping the rate of infection low. Certainly, many antiretroviral drugs developed in the fight against HIV have been thought to increase the potential of birth defects in the unborn children. A new study, however, shows the opposite. Indeed, it confirms a low risk of birth defects by antiretroviral medications used during pregnancy.
This study – the Pediatric HIV/AIDS Cohort Study (PHACS) Surveillance Monitoring of ART Toxicities (SMARTT) study – released its findings on 10 November 2014. Atazanavir was the only antiretroviral drug that was shown to increase the otherwise low risk of birth defects among HIV-positive women. This medication showed a 2-fold increase in the risk of birth defects, particularly musculoskeletal and skin anomalies. However, another study confirmed that at least three varied regimens of anti-HIV medications—that did not include atazanavir—was safe for women who are expecting. In fact, all other antiretroviral, anti-HIV medications tested in these studies showed no increase in the risk of birth defects. This is great news for HIV infected women who still want to become mothers. With the risks of infecting their child minimal, and the side effects almost non-existent, the hopes of researchers are high that we will find ways to altogether eliminate the transfer of HIV between mother and child.
